(2023)
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
JOURNAL OF THORACIC ONCOLOGY.
18,
12
(2023)
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
JOURNAL OF THORACIC ONCOLOGY.
18,
10
(2023)
Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01).
CANCERS.
15,
2
(2023)
Predicting tolerability of high-dose fentanyl buccal tablets in cancer patients.
PLOS ONE.
18,
1 January
(2022)
Evaluation of molecular methods for plasma detection of EGFR mutations in non-small cell lung cancer.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY.
18,
6
(2022)
COMPrehensive geriatric AsseSSment and multidisciplinary team intervention for hospitalised older adults (COMPASS): a protocol of pragmatic trials within a cohort.
BMJ OPEN.
12,
8
(2022)
Clinical outcomes and prognostic factors of cone-beam CT-guided radiofrequency ablation for pulmonary metastases in colorectal cancer patients.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY.
1,
1
(2022)
Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small-cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22.
TRANSLATIONAL LUNG CANCER RESEARCH.
11,
7
(2022)
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
JOURNAL OF THORACIC ONCOLOGY.
17,
4
(2022)
The risk of cardiovascular disease and stroke in survivors of head and neck cancer in Korea.
Health Science Reports.
5,
2
(2022)
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
CANCER.
128,
4
(2022)
Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01).
CANCER RESEARCH AND TREATMENT.
54,
1
(2021)
Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck.
ESMO Open.
6,
6
(2021)
Superselective vesical artery embolization for intractable bladder hemorrhage related to pelvic malignancy.
ACTA RADIOLOGICA.
62,
9
(2021)
Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
CANCER RESEARCH AND TREATMENT.
53,
3
(2021)
Clinicopathological characteristics and outcomes of gastrointestinal stromal tumors with high progranulin expression.
PLOS ONE.
16,
1 January
(2021)
Prevalence and predictive factors for upfront dose reduction of the first cycle of first-line chemotherapy in older adults with metastatic solid cancer: Korean cancer study group (kcsg) multicenter study.
CANCERS.
13,
2
(2020)
Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY.
146,
12
(2020)
Interference with daily functioning by breakthrough pain in patients with cancer.
SUPPORTIVE CARE IN CANCER.
28,
11
(2020)
Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma.
CANCER.
126,
20
